It has been publicized that UPM Biomedicals and PerkinElmer Health Sciences have joined together to distribute a range of GrowDex® and GrowDase™ products. The two companies working together will provide a comprehensive solution for HTS (High Throughput Screening) of 3D cell cultures in initial drug detection. The aim is to join PerkinElmer’s cell imaging and automation alongside UPM’s 3D reagent expertise.
Automated High Throughput Screening (HTS) is often utilized to appraise the benefits of candidate drugs in parallel, as well as the increasing approaches to 3D cell structure. This has created the requirement for quality reagents for HTS applications, one example of this being cancer drug screening. UPM Biomedicals has GrowDex hydrogels which mimic the environment in the human body, but with the ability to be used and tested at room temperature. This ability can be used with GrowDase to create a one- step successful recovery of cells for purification of biosynthetic products (downstream processing). This means there are consistent and valid solutions which can look at and estimate how drugs will work inside the living body.
“3D cell screening solution provided by UPM Biomedicals and PerkinElmer. “
Director at UPM Biomedicals, Johana Kuncova-Kallio, said “This solution brings together the instrument, software and cell culture matrices to make life easier for researchers, providing a high level of consistency between experiments. It will be exciting to see how this collaboration will help advance research and speed up the drug development process. Together with PerkinElmer, we have ensured that the products are ready to ship immediately.”
Perkin Elmer’s Senior Vice President Life Science, Alan Fletcher, said “Establishing the physiological relevance of potential therapeutic approaches earlier in the research cycle is crucial to advancing drug discovery, and to reducing clinical trial failure rates. By collaborating with UPM to offer its innovative 3D cell reagents, we are able to expand our offering for 3D cell culture models, further helping researchers get to the critical insights they need faster, to uncover successful drug candidates.”